1. Scrip
  2. >>Therapy Areas

Novartis’s Beovu Launch Clouded By Safety Worries

Beovu Uncertainty Should Benefit Regeneron’s Eylea

 
• By Sten Stovall

New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.

Macular degeneration
Beovu safety worries raised by American Society of Retinal Specialists

Doubts over the safety of Novartis AG’s new anti-VEGF eye drug Beovu (brolucizumab-dbll) have emerged, clouding its current launches in the US and Europe and boosting commercial prospects for other drugs in the anti-VEGF category, notably Bayer AG and Regeneron Pharmaceuticals Inc.'s Eylea (aflibercept).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

More from Therapy Areas

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.